Gene · 3316
Papers3,243
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 3,243
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Vitexin Regulates Heat Shock Protein Expression by Modulating ROS Levels Thereby Protecting against Heat-Stress-Induced Apoptosis. | Molecules | 2023 | 38005362 | PubTator, text mining | PubMed |
| Unraveling the Intricate Roles of Exosomes in Cardiovascular Diseases: A Comprehensive Review of Physiological Significance and Pathological Implications. | Int J Mol Sci | 2023 | 37958661 | PubTator, text mining | PubMed |
| Heat Shock Factor 1 Inhibition: A Novel Anti-Cancer Strategy with Promise for Precision Oncology. | Cancers (Basel) | 2023 | 37958341 | PubTator, text mining | PubMed |
| Single-cell sequencing and transcriptome analyses in the construction of a liquid-liquid phase separation-associated gene model for rheumatoid arthritis. | Front Genet | 2023 | 37953920 | PubTator, text mining | PubMed |
| Diagnostic potential of serum HSP90 beta for HNSCC and its therapeutic prognosis after local hyperthermia therapy. | PLoS One | 2023 | 37943802 | PubTator, text mining | PubMed |
| Tacrolimus reverses pemphigus vulgaris serum-induced depletion of desmoglein in HaCaT cells via inhibition of heat shock protein 27 phosphorylation. | BMC Immunol | 2023 | 37940861 | PubTator, text mining | PubMed |
| p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics. | Cell Commun Signal | 2023 | 37919729 | PubTator, text mining | PubMed |
| Liquid-Liquid Phase Separation Sheds New Light upon Cardiovascular Diseases. | Int J Mol Sci | 2023 | 37895097 | PubTator, text mining | PubMed |
| The Dynamics of Nerve Degeneration and Regeneration in a Healthy Milieu and in Diabetes. | Int J Mol Sci | 2023 | 37894921 | PubTator, text mining | PubMed |
| Searching for Atherosclerosis Biomarkers by Proteomics: A Focus on Lesion Pathogenesis and Vulnerability. | Int J Mol Sci | 2023 | 37894856 | PubTator, text mining | PubMed |
| Biomarkers in Laryngeal Squamous Cell Carcinoma: The Literature Review. | Cancers (Basel) | 2023 | 37894464 | PubTator, text mining | PubMed |
| Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments. | Cancers (Basel) | 2023 | 37894414 | PubTator, text mining | PubMed |
| Enhancing Gastric Cancer Therapeutic Efficacy through Synergistic Cotreatment of Linderae Radix and Hyperthermia in AGS Cells. | Biomedicines | 2023 | 37893084 | PubTator, text mining | PubMed |
| Crossroad between the Heat Shock Protein and Inflammation Pathway in Acquiring Drug Resistance: A Possible Target for Future Cancer Therapeutics. | Biomedicines | 2023 | 37893013 | PubTator, text mining | PubMed |
| Appropriate Genetic Approaches for Heat Tolerance and Maintaining Good Productivity in Tropical Poultry Production: A Review. | Vet Sci | 2023 | 37888543 | PubTator, text mining | PubMed |
| Clinical implications of heat shock protein 70 in oral carcinogenesis and prediction of progression and recurrence in oral squamous cell carcinoma patients: a retrospective clinicopathological study. | Eur J Med Res | 2023 | 37884988 | PubTator, text mining | PubMed |
| Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential. | J Exp Clin Cancer Res | 2023 | 37880792 | PubTator, text mining | PubMed |
| Overexpression of HSPB6 inhibits osteosarcoma progress through the ERK signaling pathway. | Clin Exp Med | 2023 | 37861934 | PubTator, text mining | PubMed |
| An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives. | Front Pharmacol | 2023 | 37860119 | PubTator, text mining | PubMed |
| Unraveling molecular networks in thymic epithelial tumors: deciphering the unique signatures. | Front Immunol | 2023 | 37849766 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3316/papers?page=7